Steven Altman Net Worth

The estimated Net Worth of Steven R Altman is at least $35.5 Million dollars as of 16 January 2024. Mr. Altman owns over 1,568 units of Dexcom Inc stock worth over $3,637,948 and over the last 16 years he sold DXCM stock worth over $31,569,801. In addition, he makes $324,596 as Independent Director at Dexcom Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Altman DXCM stock SEC Form 4 insiders trading

Steven has made over 120 trades of the Dexcom Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 1,568 units of DXCM stock worth $192,644 on 16 January 2024.

The largest trade he's ever made was exercising 284,436 units of Dexcom Inc stock on 28 August 2012 worth over $10,222,630. On average, Steven trades about 33,729 units every 38 days since 2008. As of 16 January 2024 he still owns at least 53,132 units of Dexcom Inc stock.

You can see the complete history of Mr. Altman stock trades at the bottom of the page.

Steven Altman biography

Steven R. Altman serves as Independent Director of the Company. He has served on our Board since November 2013. From November 2011 through January 2014, Mr. Altman served as the vice chairman of Qualcomm Incorporated (“Qualcomm”) and a member of Qualcomm’s Executive Committee. Mr. Altman previously served as the president of Qualcomm from July 2005 to November 2011, as Executive Vice President from November 1997 to June 2005 and as President of Qualcomm Technology Licensing from September 1995 to April 2005. Mr. Altman was the chief architect of Qualcomm’s strategy for licensing its broad intellectual property portfolio for wireless communications, which has accelerated the growth of CDMA technology. Mr. Altman received a B.S. from Northern Arizona University in Police Science and Administration and a J.D. from the University of San Diego.

What is the salary of Steven Altman?

As the Independent Director of Dexcom Inc, the total compensation of Steven Altman at Dexcom Inc is $324,596. There are 12 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.

How old is Steven Altman?

Steven Altman is 58, he's been the Independent Director of Dexcom Inc since 2013. There are 13 older and 15 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..

What's Steven Altman's mailing address?

Steven's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Dexcom Inc

Over the last 19 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff, and Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.

What does Dexcom Inc do?

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Complete history of Mr. Altman stock trades at Dexcom Inc and Qualcomm

Dexcom Inc executives and stock owners

Dexcom Inc executives and other stock owners filed with the SEC include:

• Kevin Sayer,
  Chairman of the Board, President, Chief Executive Officer
• Quentin Blackford,
  Chief Financial Officer, Chief Operating Officer
• Richard Doubleday,
  Executive Vice President, Chief Commercial Officer
• Andrew Balo,
  Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
• Steven Pacelli,
  Executive Vice President - Strategy and Corporate Development
• Donald Abbey,
  Executive Vice President - Quality and Regulatory Affairs
• Kevin Ronald Sayer,
  Exec. Chairman, CEO & Pres
• Jacob Steven Leach,
  Exec. VP & CTO
• Bridgette Heller,
  Independent Director
• Mark Foletta,
  Lead Independent Director
• Eric Topol,
  Independent Director
• Jay Skyler,
  Independent Director
• Nicholas Augustinos,
  Independent Director
• Steven Altman,
  Independent Director
• Barbara Kahn,
  Independent Director
• Richard Collins,
  Independent Director
• Kyle Malady,
  Independent Director
• Karen Dahut,
  Independent Director
• Shelly Selvaraj,
  Senior Vice President - Information Technology
• Jeffrey Moy,
  Senior Vice President - Operations
• Jereme Sylvain,
  Senior Vice President - Finance, Chief Accounting Officer
• Patrick Murphy,
  Executive Vice President, Chief Legal Officer
• Jake Leach,
  Executive Vice President, Chief Technology Officer
• Shelly Ramasamy Selvaraj,
  Sr. VP of Information Technology
• Donald M. Abbey,
  Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs
• Steven R. Pacelli,
  Exec. VP & MD of Dexcom Ventures
• Andrew K. Balo,
  Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.
• Sadie M. Stern,
  Exec. VP & Chief HR Officer
• Chad M. Patterson,
  Exec. VP of Global Marketing
• Sean Christensen,
  Director of Corp. Affairs & Head of Investor Relations
• Jereme M. Sylvain,
  Exec. VP, CFO & Chief Accounting Officer
• John Lister,
  VP, Legal Affairs
• Terrance H Gregg,
  Director
• Jess Roper,
  VP, CFO
• Jorge A Valdes,
  Vice President of Engineering
• Girish Naganathan,
  EVP Chief Technology Officer
• Heather S Ace,
  SVP Human Resources
• Kevin M Sun,
  VP, Corp Controller & Treasury
• Jonathan T Md Lord,
  Director
• Glen D Nelson,
  Director
• Peter Gerhardsson,
  VP, Int'l Business Development
• David Carner,
  VP, Quality Assurance
• Laura Johnson,
  V.P., Intellectual Property
• Martin Doordan,
  Director
• Sean Carney,
  Director
• John Riolo,
  VP of Quality Assurance
• Claudia Graham,
  VP, Marketing
• Donald A Lucas,
  Director
• Donald L Lucas,
  Director
• Mark Brister,
  VP, Advanced Development Teams
• Richard Yang,
  V.P., Strategic Affairs
• James H Brauker,
  VP, Research & Development
• Rodney L Kellogg,
  Vice President of Sales
• Andrew P Rasdal,
  President and CEO
• Steven J Kemper,
  Chief Financial Officer
• Kim D Blickenstaff,
  Director
• Tae Andrews,
  Vice President of Marketing
• Paul Travelers Companies In...,
  
• Pincus Private Equity Viii ...,
  
• Brenton Karl Ahrens,
  Director
• Nancy Sfog City Management ...,
  
• Equity Partners Ii Llccanaa...,
  
• Paul Travelers Companies In...,
  
• Eric A Charmers Landing Llc...,
  
• Scott Lwindamere Llcwindame...,
  
• Equity Partners Ii Llc Waub...,
  
• Teri L Lawver,
  EVP Chief Commercial Officer
• Paul R Flynn,
  EVP Global Revenue
• Matthew Vincent Dolan,
  EVP Strategy and Corporate Dev
• Sumi Shrishrimal,
  SVP Chief Risk Officer
• Chad Patterson,
  EVP Global Marketing
• Barry J. Regan,
  EVP Operations
• Jacob Steven Leach,
  EVP, Chief Operating Officer
• Rimma Driscoll,
  Director
• Michael Jon Brown,
  EVP, Chief Legal Officer
• Sadie Stern,
  EVP, Chief HR Officer